Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Why Are States Rewriting America's Health Rules?
Research & Development Why Are States Rewriting America's Health Rules?

A conservative West Virginia lawmaker and a progressive California governor rarely find common ground, yet they have become improbable allies in a sweeping national movement to fundamentally reshape what Americans eat and how public health is managed. This decentralized but powerful crusade,

New Hope for Parkinson's as Two Therapies Near Approval
Research & Development New Hope for Parkinson's as Two Therapies Near Approval

For the millions of people living with the relentless progression of Parkinson's disease, the daily battle for motor control has long been fought with a limited and often burdensome arsenal of treatments. The landscape of this fight is on the cusp of a dramatic transformation, however, as two

Could Robotic Trousers Be Astronauts' New Space Legs?
Tech & Innovation Could Robotic Trousers Be Astronauts' New Space Legs?

The dream of long-duration missions to the Moon and Mars carries with it a harsh physiological reality: the human body, evolved for Earth's gravity, deteriorates alarmingly in space. Prolonged exposure to microgravity triggers a cascade of deconditioning effects, including severe muscle atrophy,

Can a Polyp Test Reveal Hidden Cancer Risk?
Research & Development Can a Polyp Test Reveal Hidden Cancer Risk?

A recent international study is fundamentally changing the way clinicians understand and diagnose hereditary colorectal cancer, revealing that a direct analysis of colorectal polyp DNA can uncover critical information that standard blood tests frequently overlook. This groundbreaking research, a

Could Tumor DNA Redefine Cancer Treatment?
Tech & Innovation Could Tumor DNA Redefine Cancer Treatment?

A landmark clinical analysis has provided compelling evidence that the future of oncology may be found within the very code that fuels the disease, demonstrating that treatments personalized to a tumor's unique genetic profile can dramatically improve patient outcomes. This pivotal research

Are Worms Our Allies Against Antibiotic Resistance?
Research & Development Are Worms Our Allies Against Antibiotic Resistance?

The silent pandemic of antibiotic resistance, a threat the World Health Organization has elevated to one of the greatest dangers to modern medicine, has an unexpected and pervasive accomplice in the fields and farms that feed the world. A primary pathway for this threat originates in livestock

Pulmocide Halts Fungal Drug Trial Over Mortality Risk
Research & Development Pulmocide Halts Fungal Drug Trial Over Mortality Risk

The development of new medicines for the most critically ill patients is a path fraught with immense challenges, where promising breakthroughs can be abruptly overshadowed by unforeseen safety concerns. In a significant and unexpected development, London-based biopharmaceutical company Pulmocide

Do Food Preservatives Increase Your Cancer Risk?
Research & Development Do Food Preservatives Increase Your Cancer Risk?

A landmark French study involving over 100,000 adults has brought renewed scrutiny to the grocery aisle, suggesting a significant association between higher dietary exposure to specific food preservatives and a modestly increased incidence of cancer. The research, published in The BMJ , leverages

Is the System Failing Kids With Congenital Heart Disease?
Tech & Innovation Is the System Failing Kids With Congenital Heart Disease?

Congenital heart disease stands as the most common and resource-intensive birth defect in the United States, thrusting thousands of families each year into a world of high-stakes surgeries and lifelong medical care. While the clinical focus has traditionally been on the patient's condition and the

Study Pinpoints Cellular Origin of Common Brain Cancer
Research & Development Study Pinpoints Cellular Origin of Common Brain Cancer

We are joined by biopharma expert Ivan Kairatov to discuss a groundbreaking discovery that redefines our understanding of IDH-mutant glioma, the most common malignant brain tumor in young adults. This conversation explores how this cancer begins not as a visible mass, but as a stealthy infiltration

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later